UNIVERSITY OF CALIFORNIA, LOS ANGELES **UCLA**

BERKELEY • DAVIS • IRVINE • LOS ANGELES • MERCED • RIVERSIDE • SAN DIEGO • SAN FRANCISCO • SANTA BARBARA • SANTA CRUZ

OFFICE OF THE CHANCELLOR
BOX 951405
LOS ANGELES, CALIFORNIA 90095-1405

June 22, 2016

President Janet Napolitano
University of California, Office of the President
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200

Dear President Napolitano:

I am writing to advise you that I approved the request of Gregory Cole, Ph.D., Professor-in-Residence of Neurology and Medicine, UCLA David Geffen School of Medicine, Interim Director of the Mary S. Easton Alzheimer Center, Associate Director of Research GRECC GLA VA, to accept support from Akros Pharma, Inc., a U.S. subsidiary of Japan Tobacco Inc.

Following Regental regulation RE-89, before approving this request, the proposal was examined independently by a Committee of three faculty members: Professor Alcino J. Silva, Ph.D., Departments of Neurobiology, Psychiatry & Biobehavioral Sciences, and Psychology, Director, Integrative Center for Learning and Memory Brain Research Institute; Professor Nigel T. Maidment, Ph.D., Hatos Center for Neuropharmacology, Department of Psychiatry and Biobehavioral Sciences Semel Institute for Neuroscience and Human Behavior; and Professor Ming Guo, M.D., Ph.D., UCLA DGSOM Department of Neurology. The Committee unanimously and strongly supports allowing Professor Cole to accept the support from Akros Pharma, Inc. for research on preclinical development of novel anti-diabetics as broad spectrum Alzheimer's disease therapeutics. On the basis of their review, I have approved the project. The support will be in the form of supplies for this project and hosting a visiting scientist from Akros in the Cole laboratory. Ann R. Karagozian, Interim Vice Chancellor for Research, has endorsed the review panel's recommendations. Enclosed for your information are Vice Chancellor Karagozian's letter and the review letters submitted by Professors Silva, Maidment and Guo.

Sincerely,

Gene D. Block
Chancellor

Enclosures: As stated

cc: Interim Vice Chancellor for Research Ann Karagozian
Professor Greg Cole
Assistant Vice Chancellor - Research Ann Pollack
Research Policy & Compliance Coordinator Claudia Modlin

UCLA *Vice Chancellor for Research*

Ann R. Karagozian, Ph.D.
2147 Murphy Hall
140501
Phone: (310) 825-7943
Fax: (310) 206-6030
Email: akaragozian@conet.ucla.edu

June 22, 2016

Chancellor Gene D. Block
2147 Murphy Hall
14051

Dear Chancellor Block:

Professor Gregory Cole, Ph.D., Professor-in-Residence of Neurology and Medicine, David Geffen School of Medicine, Interim Director of the Mary S. Easton Alzheimer Center, Associate Director of Research GRECC GLA VA, is seeking research support from Akros Pharma, Inc., a U.S. subsidiary of Japan Tobacco Inc. Professor Cole made a request in April to receive $101,619 for supplies and to host a visiting researcher from Akros Pharma to support a project titled, "Effect of dual IRA in AD Tg models (Tg APPsw/PS1deltaE9) rats and mice." The project will investigate two types of incretin receptor agonists in ameliorating Alzheimer's disease pathology in animal models.

Regental resolution RE-89 was adopted in September 2007 and governs the acceptance of funding from the tobacco industry by the University of California. In this instance, although the research does not involve tobacco or tobacco related products, it is supported by Akros Pharma. Given that fact, I felt UCLA should engage in a special review as mandated by the Regental resolution. Therefore, I asked three UCLA faculty members, Professors Alcino J. Silva, Ph.D., Nigel T. Maidment, Ph.D., and Ming Guo, M.D., Ph.D., to review this proposed study and provide independent recommendations on whether the request for support should be approved.

As you can see from the enclosed letters from Professors Silva, Maidment and Guo, it is clear the program that Dr. Cole would like to pursue is of very high quality. All three reviewers have agreed the project uses sound methodology and that Dr. Cole has the expertise to carry out this significant study. I fully concur with this conclusion.

RE-89 requires the Chancellor to make the final determination about whether the campus can submit proposals for research support from the tobacco industry. On the basis of the reviews that Professors Silva, Maidment and Guo have conducted, I recommend you approve this request for support. RE-89 requires you to provide Dr. Cole, the UC President and the Regents with copies of your written determination approving or disapproving this request for support from Akros Pharma, Inc. and providing a rationale for the decision. I trust the materials enclosed will allow you to reach such a determination. I am also happy to answer any questions you may have.

Sincerely,

Ann R. Karagozian
Interim Vice Chancellor for Research

Enclosures: As stated

cc: Assistant Vice Chancellor- Research Ann Pollack

Modlin, Claudia

From: Alcino Silva <alcinojsilva@gmail.com>
Sent: Tuesday, May 24, 2016 4:57 PM
To: Karagozian, Ann
Cc: Block, Gene; Pollack, Ann
Subject: Re: Review of Greg Cole's request for research support from Akros Pharma Inc.

Dear Dr. Karagozian,

I am delighted to confirm that the proposal entitled "Effect of dual IRA in AD Tg models (Tg APPsw/PS1deltaE9) rats and mice" by Dr. Greg Cole (research support from Akros Pharma Inc.) uses sound methodology and the design is appropriate for the goals designated. Importantly, Dr. Greg Cole has extensive experience with many of the approaches of the proposal and I have no doubts that his lab will be able to carry out the work in accordance with the highest standards of the field. Therefore, my recommendation is that the proposal should be approved for submission without any changes.

Alcino J. Silva
UCLA Distinguished Professor
Departments of Neurobiology, Psychiatry & Biobehavioral Sciences, and Psychology, Director, Integrative Center for Learning and Memory Brain Research Institute.
695 Charles Young Drive South, Room 2357 Gonda Building Box 951761, UCLA Los Angeles, California 90095-1761

silvaa@mednet.ucla.edu
www.silvalab.org
Direct Ph 310 794 6345
Office Ph 310 794 5981
Lab Fax 310 794 7088

> On May 24, 2016, at 4:31 PM, Pollack, Ann <APollack@research.ucla.edu> wrote:
>
> Dear Dr. Silva:
>
> Please see the attached letter from Vice Chancellor Karagozian.
>
> Thank you,
>
>
> Ann Pollack
> Assistant Vice Chancellor – Research
> Special Assistant to the Vice Chancellor – Academic Personnel UCLA
> 11100 Kinross Avenue, Suite 340
> Los Angeles, California 90095-1406
> Tel: 310-794-0387
> Fax: 310-943-1981
> e-mail: apollack@research.ucla.edu
>
>
>
>

Modlin, Claudia

From: Maidment, Nigel T.
Sent: Friday, June 10, 2016 11:30 AM
To: Karagozian, Ann
Cc: Pollack, Ann
Subject: Greg Cole Proposal

This contract proposal is an adjunct to a larger proposal to compare the effectiveness of two types of incretin receptor agonists in ameliorating AD pathology in animal models. This is a "hot topic" in AD research due to evidence the insulin resistance is a risk factor for the disease. The possibility that brain insulin resistance may develop to a significant degree before detectable signs of diabetes due to peripheral changes in insulin signaling makes this a worthy avenue of investigation, particularly since simple retargeting of existing diabetic drugs to AD may be effective. Understanding the mechanisms underlying brain insulin resistance and the means by which current drugs reverse this effect may also shed light on new targets for drug action.

The experimental design and endpoints are clear, straightforward and logical. A comprehensive range of behavioral, biochemical and cytopathological measures will be employed. The inclusion of a rat model that more closely recapitulates human pathology compared with the mouse models is a strength. While specific details of the experimental procedures are lacking in some instances (due to the nature of the short contract proposal), when considered in light of the RO1 proposal to which it is appended, it is evident that the investigators pocess the necessary knowledge and expertise to carry out this interesting and translationally significant study.

Nigel T. Maidment, Ph.D.
Professor
Hatos Center for Neuropharmacology
Department of Psychiatry and Biobehavioral Sciences
Semel Institute for Neuroscience and Human Behavior
UCLA
760 Westwood Plaza
Los Angeles CA 90024

nmaidmen@ucla.edu
310 206 7767

This is an interesting and timely proposal that seeks to test drugs that work by targeting brain insulin resistance. The goals of the proposal are straightforward and appropriate. In brief, the authors will test the ability of dual agonist incretin agonists for their ability to prevent brain insulin resistance and development of features of AD in a rat model, which recapitulates many of the features of AD in humans. They also use a mouse model for some work, as the mouse system is more prevalent in the literature, and can be introduced into various genetic backgrounds. As a part of this, the authors have developed a number of bioassays that allows them to look at various aspects of insulin signaling and glucose utilization, as well as behavioral, biochemical and histological markers of AD progression and pathogenesis.

Other work, by these authors and others, reports exciting preliminary data showing the ability of incretin agonists to modify insulin signaling in the brain, and markers of AD progression. This proposal takes this work to a new and exciting level, with a focus on the most potent of the dual incretin agonists and a number of assays. It is likely that interesting observations will come from this work, and that these will be used to guide clinical studies in humans.

An important component of this work is training of a recent PhD from JT, which will facilitate their development and use of in-house assays. This is a completely appropriate arrangement. In addition, it will serve to create an environment in which future collaborations can occur.